Does the FDA guidance differ by age group

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, the FDA does not create different hormone therapy rules for different ages. The official guidance is the same for everyone.
What changes with age is how clinicians apply that guidance, because a woman's risks shift over time.

How FDA Guidance Works

According to FDA.gov, the FDA's universal message is to use the lowest effective dose for the shortest duration needed to treat menopausal symptoms. This applies to all ages. The FDA does not set age cutoffs, preferred ages, or age-based restrictions.

The reason is straightforward: the FDA regulates the medication itself, not the patient population. The FDA approves products and provides safety labeling, and then clinicians tailor treatment individually in consultation with a qualified prescriber.

Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

How Age Alters Clinical Decision-Making (Even Though FDA Rules Don't Change)

• Under age 60 or within 10 years of menopause: This group generally has a lower baseline risk of heart disease and stroke. Because of that, clinicians may feel more comfortable using systemic hormones when symptoms are significant. This is based on modern research, not an FDA age rule. A qualified prescriber should evaluate individual risk factors.
• Over age 60 or more than 10 years since menopause: According to FDA Drug Safety Communication, baseline risks for blood clots, stroke, heart disease, and dementia may rise naturally with age. Commercially available hormone therapy products are not suddenly contraindicated, but they interact with an older cardiovascular system differently. According to FDA-approved prescribing information, these risks are disclosed in boxed warnings, and clinicians review them carefully. These are clinical judgments to be made with a qualified prescriber, not FDA requirements.
• Any age needing vaginal estrogen: Local vaginal estrogen, used for dryness or painful intercourse, is considered lower risk at any age because bloodstream absorption is minimal. According to FDA.gov, the FDA labeling applies equally, but use across age groups may vary based on individual clinical assessment by a qualified prescriber.

What the FDA Actually Emphasizes

• Use the lowest dose that controls symptoms.
• Reassess regularly. According to FDA.gov, the FDA expects ongoing evaluation, not automatic continuation indefinitely.
• Know the risks listed on the label. According to FDA-approved prescribing information, these include clot risk, stroke risk, and for combined therapy, a potential change in breast cancer risk over time.

The Bottom Line

According to FDA.gov, the FDA does not have separate hormone therapy guidance for younger or older women. All age-related differences in practice come from clinical judgment, not FDA rules. A qualified prescriber will consider personal history, symptoms, and cardiovascular risk — factors that matter far more than age alone.